UK markets close in 7 hours 45 minutes
  • FTSE 100

    7,536.51
    +62.49 (+0.84%)
     
  • FTSE 250

    19,306.26
    +13.91 (+0.07%)
     
  • AIM

    849.52
    -1.40 (-0.16%)
     
  • GBP/EUR

    1.1606
    +0.0041 (+0.36%)
     
  • GBP/USD

    1.2057
    +0.0092 (+0.77%)
     
  • BTC-GBP

    13,686.32
    +151.43 (+1.12%)
     
  • CMC Crypto 200

    389.65
    +9.36 (+2.46%)
     
  • S&P 500

    3,963.94
    -62.18 (-1.54%)
     
  • DOW

    33,849.46
    -497.57 (-1.45%)
     
  • CRUDE OIL

    78.93
    +1.69 (+2.19%)
     
  • GOLD FUTURES

    1,769.30
    +14.00 (+0.80%)
     
  • NIKKEI 225

    28,027.84
    -134.99 (-0.48%)
     
  • HANG SENG

    18,204.68
    +906.74 (+5.24%)
     
  • DAX

    14,400.90
    +17.54 (+0.12%)
     
  • CAC 40

    6,685.71
    +20.51 (+0.31%)
     

Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences

CAMBRIDGE, Mass., August 31, 2022--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference.

2022 Wells Fargo Healthcare Conference
Date: Friday, September 9, 2022
Time: 8:00 a.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: In-person fireside chat and 1-on-1 meetings
Webcast Registration Link

H.C. Wainwright 24th Annual Global Investment Conference
Date: Monday, September 12, 2022
Time: Presentation available at 7:00 a.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: Virtual company presentation and 1-on-1 meetings
Webcast Registration Link

A replay of the presentations will be available in the Investors/Media section of Infinity's website at www.infi.com for 90 days following the events.

About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company"), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005151/en/

Contacts

Investor Relations:
Kevin Lui
Real Chemistry
klui@realchemistry.com